Peter Ho

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 597 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

Wenle Xia, Lei-Hua Liu, Peter Ho et al. · Oncogene · 2004 · 253 citations

Signal Transduction, Heterodimer Formation, Signaling Pathway +8

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 163 citations

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

Anna Maria Storniolo, Mark D. Pegram, Beth Overmoyer et al. · Journal of Clinical Oncology · 2008 · 119 citations · Full text

Prenatal Detection of Neuroblastoma: A Ten-Year Experience From the Dana-Farber Cancer Institute and Children's Hospital

Peter Ho, Judy A. Estroff, Harry P. Kozakewich et al. · PEDIATRICS · 1993 · 110 citations